Synageva BioPharma™ to Present at the Cowen and Company Health Care Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--

Synageva BioPharma Corp. (Synageva) GEVA, a biopharmaceutical company developing therapeutic products for rare diseases, today announced its presentation at the upcoming Cowen and Company 34^th Annual Health Care Conference being held in Boston, MA.

Sanj K. Patel, President and Chief Executive Officer of Synageva, will present on Tuesday, March 4, 2014, at 9:20 a.m. EST. The presentation will be webcast live and may be accessed from the “Webcasts & Presentations” section of the Investor Relations tab on the home page of Synageva's website at www.synageva.com.

Synageva routinely posts information that may be important to investors in the “Investor Relations” section of the company's website at www.synageva.com. Synageva encourages investors and potential investors to consult this website regularly for important information about the company.

Further information regarding Synageva BioPharma Corp. is available at www.synageva.com.

Forward-Looking Statements

This news release contains “forward-looking statements”. Such statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “intend,” “believe,” “may,” “will,” “estimate,” “forecast,” “project,” or words of similar meaning. Many factors may cause actual results to differ materially from those expressed or implied by forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, including, risk of delays in completing our clinical trials, risk that the outcomes of our clinical trials may not support registration or further development of our product candidates due to safety, efficacy or other reasons, the content and timing of decisions by the U.S. Food and Drug Administration and other regulatory authorities, and the risks identified under the heading “Risk Factors” in Synageva's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 4, 2013 and other filings Synageva periodically makes with the SEC, and others of which are not known. No forward-looking statement is a guarantee of future results or events, and investors should avoid placing undue reliance on such statements. Synageva undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Our business is subject to substantial risks and uncertainties, including those referenced above.

“Dedicated to Rare Diseases®” is a registered trademark of Synageva BioPharma Corp. “Synageva BioPharma™” is a trademark of Synageva BioPharma Corp.